The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats

Background: Sodium-glucose Cotransporter-2 inhibitors [SGLT2Is] are new antidiabetic group. Canagliflozin is the first member in this drug class approved for management of patient with type 2 diabetes (T2DM), that affects reabsorption of glucose from kidney, but its impact on kidney structure and fu...

Full description

Bibliographic Details
Main Authors:	Manal M.G. Mourad*, Fares E.M Ali, Sabah A. Fadel, Reham A.M. Ellisy
Format:	Article
Language:	English
Published:	South Valley University, Faculty of Medicine 2023-07-01
Series:	SVU - International Journal of Medical Sciences
Subjects:	canagliflozin diabetic nephropathy renoprotection sglt2 inhibitors
Online Access:	https://svuijm.journals.ekb.eg/article_318205.html

Similar Items

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
by: Takashi Wada, et al.
Published: (2022-01-01)

Canagliflozin review – safety and efficacy profile in patients with T2DM
by: Jakher H, et al.
Published: (2019-02-01)

Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway
by: Mohamed S. Dabour, et al.
Published: (2023-08-01)

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
by: Juan J. Gorgojo-Martínez, et al.
Published: (2020-07-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension
by: Xiaojun Chen, et al.
Published: (2024-05-01)

Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study)
by: Sawako Kato, et al.
Published: (2023-08-01)

Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
by: Juan J. Gorgojo-Martinez, et al.
Published: (2022-09-01)

SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia
by: Ching-Tien Lee, et al.
Published: (2023-12-01)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
by: Taha Sen, et al.
Published: (2021-12-01)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
by: Juan J. Gorgojo-Martinez, et al.
Published: (2023-06-01)

The Protective Effect of Garlic Extract on Diabetic Nephropathy
by: Mahmoud Rafieian-Kopaei, et al.
Published: (2013-10-01)

Case Report: Post-gastrectomy reactive hyperinsulinemic hypoglicaemia: glucose trends before and after canagliflozin treatment
by: G. Bellastella, et al.
Published: (2023-08-01)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
by: Seko Y, et al.
Published: (2018-11-01)

Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
by: Masa-Ki Inoue, et al.
Published: (2019-07-01)

Contrast induced nephropathy; recent findings
by: Mardani Saeed, et al.
Published: (2013-04-01)

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
by: Messana JA, et al.
Published: (2017-02-01)

Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy
by: Xin Lv, et al.
Published: (2022-12-01)

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
by: Νarjes Nasiri-Ansari, et al.
Published: (2018-07-01)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease
by: Gabriela Dumitrita Stanciu, et al.
Published: (2023-11-01)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
by: Robert A. Fletcher, et al.
Published: (2023-07-01)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
by: Masafumi Fukuda, et al.
Published: (2020-01-01)

Canagliflozin Ameliorates Oxidative Stress and Autistic-like Features in Valproic-Acid-Induced Autism in Rats: Comparison with Aripiprazole Action
by: Mohammed Moutaz Nakhal, et al.
Published: (2023-05-01)

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)

Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
by: Adrian Post, et al.
Published: (2020-05-01)

Patients with Hypertensive Nephropathy and Chronic Kidney Disease Might Not Benefit from Strict Blood Pressure Control
by: Simone Vettoretti, et al.
Published: (2018-11-01)

Comprehensive review of SGLT2 inhibitors’ efficacy through their diuretic mode of action in diabetic patients
by: Cesar Ernesto Lam-Chung
Published: (2023-07-01)

Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice
by: Peiyang Song, et al.
Published: (2022-12-01)

The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Evolving Pandemic Diabetic Nephropathy
by: Eli A. Friedman
Published: (2010-07-01)

Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
by: Elmar Zügner, et al.
Published: (2022-07-01)

Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study
by: Sammar Fathy Elhabal, et al.
Published: (2023-12-01)

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus
by: Rong Qiu, MD, PhD, et al.
Published: (2014-06-01)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
by: Hideyuki Okuma, et al.
Published: (2021-07-01)

SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
by: Mieczysław Dutka, et al.
Published: (2022-11-01)

Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
by: Pei-Chien Tsai, et al.
Published: (2023-03-01)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)